Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Giovanni Martinelli(University of Bologna), Catherine Tuglus(Amgen (United States)), Oliver G. Ottmann(Cardiff University), Xiaoyue Zhao(Amgen (United States)), Josep‐María Ribera(Universitat Autònoma de Barcelona), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Hervé Dombret(University of London Institute in Paris), Christopher Kim(Amgen (United States)), Anthony S. Stein(University of Hohenheim)
Cited by 76
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k